+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Singapore Generics Market Summary, Competitive Analysis and Forecast to 2027

  • PDF Icon

    Report

  • 46 Pages
  • July 2023
  • Region: Singapore
  • MarketLine
  • ID: 5650875
Generics in Singapore industry profile provides top-line qualitative and quantitative summary information including: market size (value 2017-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.
  • The Singaporean generics market had total revenues of $0.4 billion in 2022, representing a compound annual growth rate (CAGR) of 3.9% between 2017 and 2022.
  • Market consumption volume increased with a CAGR of 0.5% between 2017 and 2022, to reach a total of 90.3% in 2022.
  • With the rising aging population, healthcare costs continue to be a top concern for patients and rising pharmaceutical costs are putting strain on public and private health funding systems. As a result, using generic medications has proven to be a successful way to cut costs without sacrificing care quality.

Scope

  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Singapore
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Singapore
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Singapore generics market with five year forecasts

Reasons to Buy

  • What was the size of the Singapore generics market by value in 2022?
  • What will be the size of the Singapore generics market in 2027?
  • What factors are affecting the strength of competition in the Singapore generics market?
  • How has the market performed over the last five years?
  • What are the main segments that make up Singapore's generics market?

Table of Contents

1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths of the leading players?
7.3. Have there been any recent developments in the market?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Pfizer Inc.
8.3. Abbott Laboratories
8.4. Viatris Inc.
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related Research
10.4. About the Publisher
List of Tables
Table 1: Singapore generics market value: $ million, 2017-22
Table 2: Singapore generics market volume: %, 2017-22
Table 3: Singapore generics market geography segmentation: $ million, 2022
Table 4: Singapore generics market value forecast: $ million, 2022-27
Table 5: Singapore generics market volume forecast: %, 2022-27
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Pfizer Inc.: key facts
Table 10: Pfizer Inc.: Annual Financial Ratios
Table 11: Pfizer Inc.: Key Employees
Table 12: Pfizer Inc.: Key Employees Continued
Table 13: Abbott Laboratories: key facts
Table 14: Abbott Laboratories: Annual Financial Ratios
Table 15: Abbott Laboratories: Key Employees
Table 16: Abbott Laboratories: Key Employees Continued
Table 17: Viatris Inc.: key facts
Table 18: Viatris Inc.: Annual Financial Ratios
Table 19: Viatris Inc.: Key Employees
Table 20: Viatris Inc.: Key Employees Continued
Table 21: Singapore size of population (million), 2018-22
Table 22: Singapore gdp (constant 2005 prices, $ billion), 2018-22
Table 23: Singapore gdp (current prices, $ billion), 2018-22
Table 24: Singapore inflation, 2018-22
Table 25: Singapore consumer price index (absolute), 2018-22
Table 26: Singapore exchange rate, 2018-22
List of Figures
Figure 1: Singapore generics market value: $ million, 2017-22
Figure 2: Singapore generics market volume: %, 2017-22
Figure 3: Singapore generics market geography segmentation: % share, by value, 2022
Figure 4: Singapore generics market value forecast: $ million, 2022-27
Figure 5: Singapore generics market volume forecast: %, 2022-27
Figure 6: Forces driving competition in the generics market in Singapore, 2022
Figure 7: Drivers of buyer power in the generics market in Singapore, 2022
Figure 8: Drivers of supplier power in the generics market in Singapore, 2022
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Singapore, 2022
Figure 10: Factors influencing the threat of substitutes in the generics market in Singapore, 2022
Figure 11: Drivers of degree of rivalry in the generics market in Singapore, 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Teva Pharmaceutical Industries Limited
  • Pfizer Inc.
  • Abbott Laboratories
  • Viatris Inc.